Ally Bridge Group NY LLC Grows Position in Enliven Therapeutics, Inc. $ELVN

Key Points

• Ally Bridge Group NY LLC increased its stake in Enliven Therapeutics by 19.8%, acquiring an additional 28,064 shares, making it the 12th largest position in their portfolio.
• A number of institutional investors, including Polar Capital and Janus Henderson Group, significantly increased their holdings in Enliven Therapeutics during the last quarter, indicating strong investor interest.
• Analysts have mixed ratings on Enliven Therapeutics, with target prices ranging from $27 to $52, and a consensus average price target of $41.20.

Ally Bridge Group NY LLC raised its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 19.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 169,774 shares of the company's stock after buying an additional 28,064 shares during the quarter. Enliven Therapeutics makes up approximately 3.0% of Ally Bridge Group NY LLC's portfolio, making the stock its 12th biggest position. Ally Bridge Group NY LLC owned approximately 0.35% of Enliven Therapeutics worth $3,341,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Enliven Therapeutics by 3.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,036 shares of the company's stock valued at $451,000 after buying an additional 718 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Enliven Therapeutics by 230.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after purchasing an additional 1,114 shares during the last quarter. MetLife Investment Management LLC raised its stake in shares of Enliven Therapeutics by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 21,746 shares of the company's stock worth $489,000 after purchasing an additional 1,285 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of Enliven Therapeutics by 10.2% during the fourth quarter. California State Teachers Retirement System now owns 20,914 shares of the company's stock worth $471,000 after purchasing an additional 1,940 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Enliven Therapeutics by 17.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,627 shares of the company's stock worth $307,000 after purchasing an additional 1,980 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.

Insider Buying and Selling

In related news, insider Joseph P. Lyssikatos sold 7,500 shares of the stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $20.01, for a total transaction of $150,075.00. Following the transaction, the insider directly owned 940,188 shares in the company, valued at approximately $18,813,161.88. This represents a 0.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Anish Patel sold 6,667 shares of the stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $18.24, for a total value of $121,606.08. Following the transaction, the chief operating officer owned 289,975 shares in the company, valued at $5,289,144. This trade represents a 2.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 104,234 shares of company stock worth $2,186,231 in the last ninety days. 25.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ELVN shares. Robert W. Baird upped their price target on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a research note on Monday, June 16th. HC Wainwright upped their price objective on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a report on Wednesday, July 2nd. Jones Trading dropped their price objective on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a report on Friday, May 16th. Finally, The Goldman Sachs Group assumed coverage on Enliven Therapeutics in a report on Monday, June 16th. They set a "buy" rating and a $37.00 price objective on the stock. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Enliven Therapeutics presently has an average rating of "Buy" and an average price target of $41.20.

Enliven Therapeutics Price Performance

Enliven Therapeutics stock traded up $0.14 during trading hours on Friday, hitting $20.15. The stock had a trading volume of 432,313 shares, compared to its average volume of 397,903. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -10.08 and a beta of 0.89. Enliven Therapeutics, Inc. has a 1-year low of $13.30 and a 1-year high of $30.03. The stock's fifty day moving average is $20.39 and its two-hundred day moving average is $19.75.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04. As a group, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.